reason report
tafa outlook intact adjust posit deal term pt
bottom line follow yesterday morn announc
morphosyss global commerci develop agreement
mp adjust model
increas price target larg driven
favor financi term associ transact given
limit capabl outsid us adjust
revenu forecast tafasitamab tafa financi consider
up-front equiti invest mileston
eu royalti offer immedi valu investor view even
top-lin forecast remain unchang morphosi stock trade
yesterday reflect broad concern incyt
limit commerci experi scale intern market
lack clariti develop plan limit combin
develop opportun synergi cautious optimist
collabor program sinc deal bring morphosi
attract guarante up-front equiti conting mileston
payment well robust royalti ultim success
tafasitamab rest parti collect commerci effort
us commerci execut outsid us
forecast account materi lower develop commerci
expens mor tafasitamab although partial off-set
expect profit split us base lower expens
higher cash increas price target
reiter op rate stock
tafasitamab forecast unchang price target increas
driven favor financi term lower
expens expect rel uncompl transact
close quarter cash inflow morphosi
up-front payment plu equiti invest also expect
compani receiv total mileston payment
annual sale tafasitamab hit reduc
morphosyss report revenu tafasitamab ex-u market
account mid-teen mid-twenti percentag royalti eu
updat global total mor revenu increas significantli
larg due expect mileston payment
revenu decreas due lower revenu
royalti eu latest consensu updat
reflect deal updat total revenu forecast
consensu higher flat
lower expens side cog estim
includ us profit/loss share increas
compani inform svb leerink llc research
revenu mm
dcf analysi discount rate
net debt total capit
year price history/av daili volume mil mor gy
pleas refer page import disclosur price chart analyst certif
expect cog profit share reduc
expect lower sg lower estim
reflect expens share mani detail
term disclos close date mileston payment
term updat model reflect best assess like
financi impact element partnership base
chang price target morphosi increas
us adr rate stock remain outperform
price target morphosi mor us adr rate stock
outperform morphosi german biopharmaceut compani long legaci innov
therapeut monoclon antibodi discoveri develop histor morphosi taken
care path build broad portfolio skinni collabor bigger biopharma
compani result potenti low-to-mid singl digit royalti product
collabor final come fruition first reach market
tremfya begin gener royalti morphosi larger basi
compani valu howev morphosi tafasitamab hematolog
malign global collabor collabor program
deal certainli bring morphosi attract guarante up-front equiti conting
mileston payment well robust royalti ultim success tafasitamab
rest parti collect commerci effort us incyt commerci
execut outsid us tafasitamab shown impress data single-arm phase ii trial
patient transplant-inelig relaps refractori dlbcl endors
us fda data appear suffici acceler approv tafasitamab
abl gener revenu rang still
potenti develop larger popul sever differ form non-hodgkin
lymphoma nhl import asset mor stock royalti jnj op il-
antibodi psoriasi estim worth today could increas
substanti revenu exce perform product indic
royalty-bear product agreement contribut anoth compani outstand
cash reserv add anoth give total valu per share
price target mor base dcf methodolog cash flow
termin growth driver forecast royalti tremfya risk-
adjust sale tafasitamab assum discount rate base compani wacc
addit factor mor cash balanc valuat
risk view outlook valuat morphosi includ failur obtain approv
tafasitamab either us ex-u jurisdict base l-mind forecast
product also subject risk better-than-expect market share gain
competit brand product roch polatuzumab lack willing
physician patient chang new treatment tafasitamab long-stand
treatment option payer us europ could also refus reimburs expens
combin tafasitamab plu revlimid could potenti cost
year treatment addit morphosi current sole sourc incom royalti tremfya
could lower expect due chang highli competit immunolog treatment
market risk morphosi includ develop regulatori disappoint
partner out-licens antibodi two product fail compani valuat
would reduc approxim
brand chemic name
type event
event trial detail
date known
specifi
up/down
svb leerink view
svb leerink llc research compani file
million
royalti mileston po adjust
svb leerink llc research compani file
million
sale
 total revenu
sg total revenu
svb leerink llc research compani file
mm
pv flow
equiti
debt
